Reduction of Cardiac Fibrosis Decreases Systolic Performance Without Affecting Diastolic Function in Hypertensive Rats

Hypertension

Volumn 43, Issue 5, 2004, Pages 1067-1073

  Cingolani, Oscar H ^a,b   Yang, Xiao Ping ^a   Liu, Yun He ^a   Villanueva, Mirko ^a   Rhaleb, Nour Eddine ^a   Carretero, Oscar A ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

Hypertension; Rats, spontaneously hypertensive

Indexed keywords

ANTIFIBROTIC AGENT; COLLAGEN; PEPTIDE; SERASPENIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SIZE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CROSS LINKING; DIASTOLE; EX VIVO STUDY; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE COMPLIANCE; HEART VENTRICLE OVERLOAD; HYPERTENSION; NONHUMAN; OSMOTIC MINIPUMP; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLE;

ANIMALS; CAPILLARIES; CELL SIZE; COLLAGEN; DIASTOLE; FIBROSIS; HEART VENTRICLES; HYDROXYPROLINE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIUM; OLIGOPEPTIDES; PRESSURE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SYSTOLE;

EID: 2342586811     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000125013.22494.c5     Document Type: Article

References (40)

1. Wachtell K, Palmieri V, Olsen MH, Gerdts E, Papademetriou V, Nieminen MS, Smith G, Dahlöf B, Aurigemma GP, Devereux RB. Change in systolic left ventricular performance after 3 years of antihypertensive treatment. The Losartan Intervention for Endpoint (LIFE) Study. Circulation. 2002;106:227-232.
2. Lip GYH. Regression of left ventricular hypertrophy and improved prognosis. Some HOPE now ... or hype? [editorial]. Circulation. 2001;104:1582-1584.
3. Liebson PR, Grandits GA, Dianzumba S, Prineas RJ, Grimm RH Jr., Neaton JD, Stamler J, for the Treatment of Hypertension Study Research Group. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1995;91:698-706.
4. Boluyt MO, Bing OHL. Matrix gene expression and decompensated heart failure: the aged SHR model. Cardiovasc Res. 2000;46:239-249.
5. Boluyt MO, O'Neill L, Meredith AL, Bing OHL, Brooks WW, Conrad CH, Crow MT, Lakatta EG. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure. Marked upregulation of genes encoding extracellular matrix components. Circ Res. 1994;75:23-32.
6. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, for the LIFE study group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.
7. Mayet J, Ariff B, Wasan B, Chapman N, Shahi M, Poulter NR, Sever PS, Foale RA, Thom SAM. Improvement in midwall myocardial shortening with regression of left ventricular hypertrophy. Hypertension. 2000;34:755-759.
8. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation. 1991;83:1771-1779.
9. Kim HE, Dalal SS, Young E, Legato MJ, Weisfeldt ML, D'Armiento J. Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J Clin Invest. 2000;106:857-866.
10. Baicu CF, Stroud ID, Livesay VA, Hapke E, Holder J, Spinale FG, Zile MR. Changes in extracellular collagen matrix alter myocardial systolic performance. Am J Physiol Heart Circ Physiol. 2003;284:H122-H132.
11. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J, Miwa T, Sugawara M, Yamaguchi Y, Ookawara T, Suzuki K, Hori M. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res. 2002;55:76-82.
12. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res. 1991;69:107-115.
13. Brooks WW, Bing OHL, Boluyt MO, Malhotra A, Morgan JP, Satoh N, Colucci WS, Conrad CH. Altered inotropic responsiveness and gene expression of hypertrophied myocardium with captopril. Hypertension. 2000;35:1203-1209.
14. Bing OHL, Brooks WW, Robinson KG, Slawsky MT, Hayes JA, Litwin SE, Sen S, Conrad CH. The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure. J Mol Cell Cardiol. 1995;27:383-396.
15. Vazeux G, Cotton J, Cuniasse P, Dive V. Potency and selectivity of RXP407 on human, rat, and mouse angiotensin-converting enzyme. Biochem Pharmacol. 2001;61:835-841.
16. Junot C, Gonzales M-F, Ezan E, Cotton J, Vazeux G, Michaud A, Azizi M, Vassiliou S, Yiotakis A, Corvol P, Dive V. RPX 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis. J Pharmacol Exp Ther. 2001;297:606-611.
17. Rhaleb N-E, Peng H, Yang X-P, Liu Y-H, Mehta D, Ezan E, Carretero OA. Long-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertension. Circulation. 2001;103:3136-3141.
18. Peng H, Carretero OA, Raij L, Yang F, Kapke A, Rhaleb N-E. Antifibrotic effects of N-acetyl-seryl-aspartyl-lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats. Hypertension. 2001;37:794-800.
19. Cingolani OH, Yang X-P, Cavasin MA, Carretero OA. Increased systolic performance with diastolic dysfunction in adult spontaneously hypertensive rats. Hypertension. 2003;41:249-254.
20. Georgakopoulos D, Mitzner WA, Chen C-H, Byrne BJ, Millar HD, Hare JM, Kass DA. In vivo murine left ventricular pressure-volume relations by miniaturized conductance micromanometry. Am J Physiol. 1998;274: H1416-H1422.
21. Feldman MD, Erikson JM, Mao Y, Korcarz CE, Lang RM, Freeman GL. Validation of a mouse conductance system to determine LV volume: comparison to echocardiography and crystals. Am J Physiol Heart Circ Physiol. 2000;279:H1698-H1707.
22. Kass DA. Clinical evaluation of left heart function by conductance catheter technique. Eur Heart J. 1992;13(Suppl E):57-64.
23. Raya TE, Gay RG, Lancaster L, Aguirre M, Moffett C, Goldman S. Serial changes in left ventricular relaxation and chamber stiffness after large myocardial infarction in rats. Circulation. 1988;77:1424-1431.
24. Susic D, Varagic J, Frohlich ED. Isolated systolic hypertension in elderly WKY is reversed with L-arginine and ACE inhibition. Hypertension. 2001;38:1422-1426.
25. Weber KT. Cardioreparation in hypertensive heart disease. Hypertension. 2001;38:588-591.
26. Burkhoff D, Maurer MS, Packer M. Heart failure with a normal ejection fraction. Is it really a disorder of diastolic function? [editorial]. Circulation. 2003;107:656-658.
27. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction. Implications for systolic and diastolic reserve limitations. Circulation. 2003;107:714-720.
28. Weiss JL, Frederiksen JW, Weisfeldt ML. Hemodynamic determinants of the time-course of fall in canine left ventricular pressure. J Clin Invest. 1976;58:751-760.
29. Nishimura H, Kubo S, Nishioka A, Imamura K, Kawamura K, Hasegawa M. Left ventricular diastolic function of spontaneously hypertensive rats and its relationship to structural components of the left ventricle. Clin Sci. 1985;69:571-580.
30. + exchanger. Cardiovasc Res. 2002;53:862-868.
31. Wu Y, Bell SP, Trombitas K, Witt CC, Labeit S, LeWinter MM, Granzier H. Changes in titin isoform expression in pacing-induced cardiac failure give rise to increased passive muscle stiffness. Circulation. 2002;106:1384-1389.
32. Kass DA. Myocardial mechanics. In: Poole-Wilson PA, Colucci WS, Massie BM, Chatterjee K, Coats AJS, eds. Heart Failure. Scientific Principles and Clinical Practice. New York: Churchill Livingstone; 1997:87-108.
33. Pokharel S, Rasoul S, Roks AJM, van Leeuwen REW, van Luyn MJA, Deelman LE, Smits JF, Carretero O, van Gilst WH, Pinto YM. N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts. Hypertension. 2002;40:155-161.
34. Kanasaki K, Koya D, Sugimoto T, Isono M, Kashiwagi A, Haneda M. N-acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-β-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells. J Am Soc Nephrol. 2003;14:863-872.
35. Yang F, Yang X-P, Liu Y-H, Xu J, Cingolani O, Rhaleb N-E, Carretero OA. Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension. 2004;43:229-236.
36. Mukhergee D, Sen S. Collagen phenotypes during development and regression of myocardial hypertrophy in spontaneously hypertensive rats. Circ Res. 1990;67:1474-1480.
37. Woodiwiss AJ, Tsotetsi OJ, Sprott S, Lancaster EJ, Mela T, Chung ES, Meyer TE, Norton GR. Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction. Circulation. 2001;103:155-160.
38. Norton GR, Tsotetsi J, Trifunovic B, Hartford C, Candy GP, Woodiwiss AJ. Myocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats. Circulation. 1997;96:1991-1998.
39. + exchange inhibition. Hypertension. 2003;41:373-377.
40. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102:1388-1393.